CORDIS · 101225153 · HORIZON
RGNcestry Tracing and harnessing the ancestry of RNA-guided nucleases
Coordinator: FOUNDATION IMMUNE ENGINEERING FOR GLOBAL CHILD AND ADOLESCENT HEALTH (CH)
The phylogenetic, biochemical and functional diversity of these linked RGNs suggest a common origin that gave rise to the innumerable variations we observe today. However, little is known about these ancestors and the evolutionary paths that led to their modern counterparts. Recently, our team showed that reconstructed ancestors of Cas9 and Cas12a RGNs exhibit flexible substrate recognition and collateral activities distinct from any modern counterpart. This work sets the stage to uncover the evolutionary trajectories that gave rise to all related RGNs and to translate insights into new and i…
About Horizon Europe (2021–2027)
Horizon Europe is the EU's current research and innovation programme, covering 2021 to 2027 with a budget of roughly €95.5 billion. Its three pillars are Excellent Science (frontier research and mobility), Global Challenges and European Industrial Competitiveness (mission-driven collaborative projects in health, climate, digital, security and food) and Innovative Europe (the EIC and EIT). It also funds five EU Missions targeting cancer, climate adaptation, smart cities, oceans and soils.
EU contribution: €10.7M awarded to the consortium. The project runs over approximately 6 years from 2026-04-01 to 2032-03-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from CH
see all →- HBP SGA1 — Human Brain Project Specific Grant Agreement 1720270 · H2020 · €89.0M
- HBP SGA2 — Human Brain Project Specific Grant Agreement 2785907 · H2020 · €88.0M
- ATTRACT2 — Breakthrough Innovation Programme for a Pan-European Detection and Imaging Eco-System – Phase-2101004462 · H2020 · €35.0M
- STEMBANCC — Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC)115439 · FP7 · €26.0M
- IABC PROGRAMME — iABC Programme115721 · FP7 · €24.3M
- ULTRA-DD — Unrestricted Leveraging of Targets for Research Advancement and Drug Discovery115766 · FP7 · €21.2M
Other HORIZON projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon Europe through a joint programme of the members of the EUROfusion consortium101052200 · DE · €549.4M
- EITUM-BP26-28 — EIT Urban Mobility Business Plan 2026-2028101269525 · ES · €206.9M
- PARC — Partnership for the Assessment of Risks from Chemicals101057014 · FR · €200.0M
- EIT RM BP23-25 — EIT RawMatrials Business Plan 2023-2025101113034 · DE · €155.5M
- SGA1-HE — COST: Europe's most empowering research programme Strengthening science and innovation through research networking101052416 · BE · €153.0M
- EIT HEI — EIT Higher Education Initiative - Scaling Europe’s Innovation Ecosystems101270329 · DE · €130.0M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon Europe (2021–2027) programme, under the HORIZON-ERC-SYG funding scheme.
- What is the EU contribution?
- The European Commission contributes €10.7M toward a total project budget of €10.7M.
- Which EU programme funds it?
- The project is funded under Horizon Europe (2021–2027), call ERC-2025-SyG.
- Who coordinates the project?
- The project is coordinated by FOUNDATION IMMUNE ENGINEERING FOR GLOBAL CHILD AND ADOLESCENT HEALTH (CH).
- What is the project timeline?
- The project runs from 2026-04-01 to 2032-03-31 — approximately 6 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 101225153.